Drug Discovery World: “Berkeley Lights: Improving antibody discovery”
Time can be the most valuable asset in the drug and therapeutic development processes, especially in situations like the COVID-19 pandemic. This Drug Discovery World story highlights the Genovac and Berkeley Lights partnership, which accelerates antibody discovery by combining our advanced genetic immunization technology with the Berkeley Lights Beacon® Optofluidic System. The combination has sped up the process so much that on a recent project we found more than 100 antibodies compared to only 15 by hybridoma across 3 GPCR targets, and we did it in less than a week. Our next goal using the Beacon is to expand our screening diversity into rabbits and alpaca.